Indications: Nerlynx® (neratinib) tablets, for oral use, is a kinase inhibitor indicated:
Dosing and Administration Guide
Review detailed information for your office staff about dosing, dose escalation, and treatment management.
ExteNET Trial
(eBC) Data
Review a brochure describing the efficacy and safety data for Nerlynx in patients with early-stage HER2+ breast cancer and subgroups of clinical interest.
eBC Treatment Completion Data
Review a brochure detailing a descriptive analysis of patients with early-stage HER2+ breast cancer who completed treatment with Nerlynx as planned in the ExteNET trial.1,*
Enrollment Form
Prescribe Nerlynx to your appropriate patients with the Enrollment Form.
Co-pay Card Program
Eligible commercially insured patients treated with NERLYNX can be enrolled for co-pay assistance.
Support for patients prescribed NERLYNX*
Puma Patient Lynx programs are subject to change or to be discontinued without notice. Limitations apply and certain programs are subject to eligibility criteria. For full terms and conditions, call 1-855-816-5421.
Download the Nerlynx Dosing and Administration Guide for additional information to help your patients get started with Nerlynx
Share important resources, such as the Mentor Program, with your patients to provide them support throughout their treatment.
HUB Resources Brochure
Review a brochure describing the upgraded patient support services available from Puma Patient Lynx.
Contraindications: None
Warnings and Precautions:
Adverse Reactions: The most common adverse reactions (reported in ≥5% of patients) were:
To report suspected adverse reactions, contact Puma Biotechnology, Inc. at 1-844-Nerlynx (1-844-637-5969) or FDA at 1-800-332-1088 or www.fda.gov/medwatch.
Drug Interactions:
Use In Specific Populations:
Please see Full Prescribing Information.
Indications: Nerlynx® (neratinib) tablets, for oral use, is a kinase inhibitor indicated: